Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann, K. Fizazi, N. Shore, T. L. Tammela, A. Ulys, E. Vjaters, S. Polyakov, M. Jievaltas, M. Luz, B. Alekseev, I. Kuss, M. -A. Le Berre, O. Petrenciuc, A. Snapir, T. Sarapohja, M. R. Smith

    Research output: Contribution to journalMeeting Abstractpeer-review

    Original languageEnglish
    Article number149
    Pages (from-to)225-225
    Number of pages1
    JournalOncology Research and Treatment
    Volume43
    Issue numberSUPPL 4
    Publication statusPublished - Oct 2020
    EventAnnual conference
    of the German, Austrian and Swiss Societies for Hematology and
    Medical oncology
    - virtual
    Duration: 9 Oct 202011 Oct 2020

    Field of Science*

    • 3.2 Clinical medicine
    • 3.1 Basic medicine

    Publication Type*

    • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

    Cite this